ArticleNature communications2023
CRISPR-induced DNA reorganization for multiplexed nucleic acid detection.
Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 61 citations in OpenAlex.
- Topology-Gated λ Exonuclease Enables Amplification-Free Signal Boosting.Journal of the American Chemical Society · 2026Article
- RAPID: evaluation of Cas12a protospacer nicking and chimeric reporters for PAM-independent RNA and DNA diagnostics.Nucleic acids research · 2026Article
- CRISPR diagnostics: from trans-nuclease activity to cancer diagnosis.Cell & bioscience · 2026Review
- Review
- Universal Regulation of DNA Polymerase via Photocaged Primer Enables Light-Start Isothermal Amplification on Demand.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Molecular point-of-care: technological evolution, clinical applications, and future perspectives.Frontiers in bioengineering and biotechnology · 2026Review
- Information Theory-Guided Detection of Biomarkers Using Programmable Aptamer Arrays.medRxiv : the preprint server for health sciences · 2025Article
- CRISPR/Cas Technology for the Diagnosis of Animal Infectious Diseases.Microorganisms · 2025Review
- NAPTUNE: nucleic acids and protein biomarkers testing via ultra-sensitive nucleases escalation.Nature communications · 2025Article
- State of the art CRISPR-based strategies for cancer diagnostics and treatment.Biomarker research · 2024Review
- Binding-driven forward tearing protospacer activated CRISPR-Cas12a system and applications for microRNA detection.Journal of nanobiotechnology · 2024Article
- Microbial biosensors for diagnostics, surveillance and epidemiology: Today's achievements and tomorrow's prospects.Microbial biotechnology · 2024Review
- CRISPR/Cas12a-mediated DNA-AgNC label-free logical gate for multiple microRNAs' assay.Mikrochimica acta · 2024Article
- Intrinsic RNA Targeting Triggers Indiscriminate DNase Activity of CRISPR-Cas12a.Angewandte Chemie (International ed. in English) · 2024Article
- Palm Multidiagnostic ofTransboundary and emerging diseases · 2024Article
- Asymmetric CRISPR enabling cascade signal amplification for nucleic acid detection by competitive crRNA.Nature communications · 2023Article
- Unmodificated stepless regulation of CRISPR/Cas12a multi-performance.Nucleic acids research · 2023Article
- Advanced Techniques Using In Vivo Electroporation to Study the Molecular Mechanisms of Cerebral Development Disorders.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 7 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nucleic acid sensing powered by the sequence recognition of CRIPSR technologies has enabled major advancement toward rapid, accurate and deployable diagnostics. While exciting, there are still many challenges facing their practical implementation, such as the widespread need for a PAM sequence in the targeted nucleic acid, labile RNA inputs, and limited multiplexing. Here we report FACT (Functionalized Amplification CRISPR Tracing), a CRISPR-based nucleic acid barcoding technology compatible with Cas12a and Cas13a, enabling diagnostic outputs based on cis- and trans-cleavage from any sequence. Furthermore, we link the activation of CRISPR-Cas12a to the expression of proteins through a Reprogrammable PAIRing system (RePAIR). We then combine FACT and RePAIR to create FACTOR (FACT on RePAIR), a CRISPR-based diagnostic, that we use to detect infectious disease in an agricultural use case: honey bee viral infection. With high specificity and accuracy, we demonstrate the potential of FACTOR to be applied to the sensing of any nucleic acid of interest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.